American Century Companies Inc. bought a new position in shares of ChemoCentryx (NASDAQ:CCXI) in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 31,279 shares of the biopharmaceutical company’s stock, valued at approximately $425,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Landscape Capital Management L.L.C. raised its position in ChemoCentryx by 35.4% during the fourth quarter. Landscape Capital Management L.L.C. now owns 33,764 shares of the biopharmaceutical company’s stock worth $201,000 after acquiring an additional 8,825 shares during the last quarter. Wells Fargo & Company MN raised its position in ChemoCentryx by 46.2% during the third quarter. Wells Fargo & Company MN now owns 34,503 shares of the biopharmaceutical company’s stock worth $255,000 after acquiring an additional 10,908 shares during the last quarter. Unterberg Capital LLC acquired a new position in ChemoCentryx during the fourth quarter worth about $595,000. Wasatch Advisors Inc. raised its position in ChemoCentryx by 9.2% during the first quarter. Wasatch Advisors Inc. now owns 2,382,932 shares of the biopharmaceutical company’s stock worth $32,408,000 after acquiring an additional 201,044 shares during the last quarter. Finally, Alps Advisors Inc. acquired a new position in ChemoCentryx during the first quarter worth about $511,000. Institutional investors own 50.09% of the company’s stock.

In related news, insider Thomas J. Schall sold 92,798 shares of the business’s stock in a transaction that occurred on Wednesday, May 23rd. The shares were sold at an average price of $12.84, for a total value of $1,191,526.32. Following the completion of the sale, the insider now directly owns 2,218,932 shares in the company, valued at $28,491,086.88. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Thomas J. Schall sold 33,938 shares of the business’s stock in a transaction that occurred on Monday, May 21st. The shares were sold at an average price of $12.55, for a total transaction of $425,921.90. Following the completion of the sale, the chief executive officer now owns 2,218,932 shares of the company’s stock, valued at $27,847,596.60. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 621,572 shares of company stock valued at $7,332,032. 14.50% of the stock is owned by insiders.

A number of equities analysts have issued reports on CCXI shares. HC Wainwright began coverage on shares of ChemoCentryx in a research report on Wednesday, May 2nd. They set a “buy” rating and a $20.00 target price for the company. ValuEngine upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating in a report on Wednesday, May 2nd. Canaccord Genuity began coverage on shares of ChemoCentryx in a report on Wednesday, May 16th. They set a “buy” rating and a $17.00 price target for the company. Zacks Investment Research upgraded shares of ChemoCentryx from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a report on Wednesday, March 14th. Finally, TheStreet upgraded shares of ChemoCentryx from a “d” rating to a “c+” rating in a report on Monday, April 16th. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $16.50.

Shares of ChemoCentryx opened at $12.98 on Friday, according to MarketBeat. The stock has a market cap of $626.66 million, a PE ratio of 36.06 and a beta of 1.63. ChemoCentryx has a 12 month low of $5.42 and a 12 month high of $15.08. The company has a quick ratio of 1.95, a current ratio of 1.95 and a debt-to-equity ratio of 0.18.

ChemoCentryx (NASDAQ:CCXI) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.19) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. The firm had revenue of $9.55 million for the quarter, compared to analysts’ expectations of $9.10 million. research analysts predict that ChemoCentryx will post -1.02 earnings per share for the current fiscal year.

ChemoCentryx Company Profile

ChemoCentryx, Inc, a clinical-stage biopharmaceutical company, develops new medications for inflammatory and autoimmune diseases, and cancer in the United States. The company targets the chemokine and chemoattractant systems to discover, develop, and commercialize orally-administered therapies. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis (AAV).

Want to see what other hedge funds are holding CCXI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ChemoCentryx (NASDAQ:CCXI).

Institutional Ownership by Quarter for ChemoCentryx (NASDAQ:CCXI)

Receive News & Ratings for ChemoCentryx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ChemoCentryx and related companies with MarketBeat.com's FREE daily email newsletter.